$KNF

Knife River Corporation (NYSE:KNF) Receives Average Rating of “Moderate Buy” from Analysts

Knife River Corp. (NYSE:KNF) received a consensus “Moderate Buy” from 10 analysts, with 6 buys, 3 holds and 1 sell, MarketBeat reports. The average 12-month price target is $97.29. Recent calls include Oppenheimer “outperform” at $95 and Stephens “overweight” raised to $105. KNF shares opened at $78.59. In its May 5 earnings, it reported EPS of -$1.40 (vs -$1.42 est.) and revenue of $410.13M (vs $387.06M est.).

Original reporting
Published Jun 1, 2026, 9:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 1, 2026, 9:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Knife River Corporation (NYSE:KNF) Receives Average Rating of “Moderate Buy” from Analysts — source image
Decision brief

The 30-second read

$KNFBullishLow
01

Why it matters

The primary tradable element is sentiment/positioning from analyst coverage updates; however, it lacks a fresh catalyst (no new guidance, contract, or operational event).

02

Market read

Useful for gauging Street positioning and near-term sentiment, but not a standalone fundamental catalyst.

03

What to watch

The article cites the May 5 earnings print but does not add new guidance; traders may weight upcoming operational/cycle data over rating changes.

Relevance 6/10Novelty 3/10Timing: pre-market/at open sentiment check on analyst consensus

Background

The article summarizes consensus analyst ratings and price targets for Knife River and reiterates recent earnings metrics (May 5).

Company-level read

Ticker impact

$KNFBullishMedium confidence
Context

Knife River is the article’s subject, with consensus “Moderate Buy” and multiple analyst target/rating changes cited.

Expected impact

Mild upside bias possible, but likely limited because this is an analyst-rating recap rather than a new fundamental event.

Evidence & confidence

The piece aggregates analyst views and targets; it does not introduce new company-specific fundamentals beyond referencing the already-reported May 5 earnings.

Market effects

Limited; analyst sentiment on one aggregates/contractor name may slightly influence peer sentiment but no sector-wide catalyst is provided.

Minor; Knife River is a western US construction materials/contracting firm, but no regional demand signal is new here.

None; the news is company-specific analyst coverage.

Counterpoint

A consensus “Moderate Buy” can mask dispersion (one sell, three holds), so the stock may not follow targets if fundamentals or guidance disappoint.

Key entities

  • Knife River Corporation

    Integrated construction materials and contracting company; subject of consensus rating and target-price discussion.

Related articles

$KNFMed

Why Shares of Knife River Were Moving Higher Today

Knife River Corporation (KNF) shares rose 3.8% after activist investor Starboard Value disclosed a stake and urged the company to explore strategic alternatives, including a potential sale. Starboard praised Knife River's assets but criticized its performance, calling for a plan to achieve 22% adjusted EBITDA by 2029. The company said it would engage with Starboard but defended its strategy.

$KNFMed

Knife River Q2 Earnings Call Highlights

Knife River (NYSE:KNF) said some Texas highway work will shift into 2027, and changes in paving versus larger roadway expansion jobs reduced Q2 adjusted EBITDA by about $8 million. CFO Nathan Ring reported aggregate volumes up 14% and raised 2026 revenue to $3.4B-$3.6B while reaffirming adjusted EBITDA guidance of $520M-$560M. Backlog rose to $1.2B.

$KNFHigh

KNIFE RIVER CORPORATION REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Knife River Corp (KNF) filed an SEC Form 8-K — Results of Operations and Financial Condition. KNIFE RIVER CORPORATION REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS • Double-digit volume and gross profit growth across material product lines • 20% growth in contracting services revenue • Sequentially increased backlog from the first quarter, to $1.2 billion • Raised guidanc

$PCVXMedAI 8/10

Vaxcyte slides as recent $1.15 billion financing weighs on shares

Vaxcyte (PCVX) shares fell 5.4% due to dilution concerns from a $1.15B financing round. The company raised funds via equity and convertible notes, with proceeds earmarked for clinical development and commercial prep. Insiders sold shares, while hedge funds showed mixed activity. Topline trial data is expected by late October 2026.

$CABOHighAI 8/10

Why Cable One (CABO) Stock Is Trading Up Today

Cable One (CABO) shares rose 8.8% after announcing a potential $2.45B refinancing deal with lenders, including GTCR. The company also stated it is not required to complete the Mega Broadband acquisition while legal restraints are in place. Shares closed at $11.82, up 2.3% from the previous close. The company's stock has been highly volatile, down 88.5% year-to-date.